First Horizon Advisors, Inc. Xencor Inc Transaction History

First Horizon Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$26.68 - $41.63 $5,229 - $8,159	-196 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$33.67 - $43.44 $4,276 - $5,516	127 Added 184.06%	196 $7,000
Q3 2021 Nov 15, 2021	SELL	$30.65 - $35.68 $3,463 - $4,031	-113 Reduced 62.09%	69 $2,000
Q3 2021 Nov 09, 2021	BUY	$30.65 - $35.68 $3,463 - $4,031	113 Added 163.77%	182 $5,000
Q2 2021 Aug 09, 2021	BUY	$34.33 - $44.68 $2,368 - $3,082	69 New	69 $2,000

214

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.09B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.